2C2-NBOMe
Chemical compound
From Wikipedia, the free encyclopedia
2C2-NBOMe, also known as 2C-MMDA-2-NBOMe or NBOMe-MMDPEA-2, is a phenethylamine derivative from the 25-NB (NBOMe) family.[1][2] It is the NBOMe derivative of 2C-MMDA-2 (MMDPEA-2).[2]
- None
| |
| Clinical data | |
|---|---|
| Other names | NBOMe-MMDPEA-2; MMDPEA-2-NBOMe; 2C-MMDA-2-NBOMe; 2C-2-NBOMe; N-(2-Methoxybenzyl)-2-methoxy-4,5-methylenedioxyphenethylamine |
| Drug class | Serotonin 5-HT2 receptor agonist; Serotonergic psychedelic; Hallucinogen |
| ATC code |
|
| Identifiers | |
| |
| Chemical and physical data | |
| Formula | C18H21NO4 |
| Molar mass | 315.369 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
It acts as a potent agonist at the serotonin 5-HT2A receptor with weaker activity at 5-HT2B and 5-HT2C, and produces a head-twitch response in animal studies which often correlates with potential for psychedelic effects in humans.[1][2]
It is related in structure to psychedelic phenethylamine derivatives such as MMDA-2 and lophophine (MMDPEA) and is the first phenethylamine derivative with a methylenedioxy substitution on the phenyl ring but no alkyl substitution on the alpha carbon, that has been shown to produce psychedelic-appropriate responding in animals.[1][2]
The drug was first described in the literature by Jason Wallach and colleagues in 2022 and 2023.[1][2] It is a controlled substance in Canada under phenethylamine blanket-ban language.[3] The drug is not an explicitly controlled substance in the United States,[4] but could be considered a controlled substance under the Federal Analogue Act if intended for human consumption.
